Ingenza e brochure 014

The importance of bio-chemistry also being sustainable

chemistry

cannot be overstated and utilising proprietary enabling technologies can be increasingly predictable,

adaptable & fertile ground innovating adapting delivering world class biotechnology

Worldwide leaders in the application of industrial biotechnology and synthetic biology, Ingenza provides efficient scalable bioprocesses to manufacture chemicals, biologics, pharmaceuticals and biofuels, from sustainable sources.

Founded in 2003, we have experienced significant growth in each year since with 78% of our people engaged within our laboratories.

Our mission is to be the partner of choice in Industrial Biotechnology and Synthetic Biology by leveraging our world class enabling technologies for sustainable integrated bioprocessing. We will achieve high growth through worldwide licensing of proprietary, game-changing technologies and strategic partnering. We will embody a culture of innovation and workplace excellence Work with Ingenza to enable ideas and you can take advantage of proprietary enabling technologies that can help unlock opportunities and transform them into sustainable manufacturing routes.

Our unique capabilities proposition revolves around implementation of our proprietary biotechnologies - combined with market leading expertise in synthetic chemistry integrating genetics, biochemistry and fermentation scale up

inaBle's one-step reaction technology has been used to assemble as many as ten different parts in one reaction, with future experiments planned to extend assembly capacity.

With Ingenza’s laboratory teams, the result is quicker, more efficient development of novel gene assemblies and at a scale and diversity previously impossible. inaBle's DNa assembly technology can be used to design sophisticated custom assemblies or to generate broad or tailored combinatorial libraries for screening and optimization of new gene pathways.

in ABLE

p r o v i d e s accelerated new product development by designing and building new DNA assemblies for synthetic biology applications. These solutions are predictable, sustainable and renewable due to a combination of revolutionary, proprietary technologies for DNA assembly - and our team of scientists immersed in fermentation, molecular biology and process development

We describe a methodology that is capable of assembling in a single reaction as many as ten parts into biological pathways using a specific restriction endonuclease and T4 DNa ligase. Furthermore, the technology allows the combination of any input part in any desired order thanks to unique compatible ends that are designed by inaBle proprietary bioinformatics software The entire process is ready to be automated offering the generation of large assemblies in a fast, reliable and robust manner. inaBle provides reliable and cost effective assemblies to its partners to help develop innovative bioproducts and processes

ASE STUD

Adapting enabling technologies: biologic production Pichia system improving product yield and quality

Customer’s challenge: US biopharma producing mammalian enzyme to GMP standard In-house E.coli system was unsuitable, yielding insoluble, inactive product Needed alternate production system yielding active, soluble protein, free of third party IP Ingenza Approach:

Demonstrated feasibility of recombinant Pichia pastoris to produce/secrete target to required yield and quality Constructed fully cGMP compliant, scalable Pichia manufacturing system with freedom to operate

Result:

Customer can meet production needs Ingenza developing recombinant Pichia for new targets Proprietary (non-methanol) Pichia protein secretion systems for the customer

ASE STUD

Enabling critical steps to novel biochemical pathways Combinatorial Genetics: Bioprocess IP development strategy

Customer’s challenge: Global leader in petroleum-based polymers needed POC for patent filings on novel biosynthetic routes All novel steps in novel biochemical pathways to be demonstrated in 1 year to establish IP position Ingenza Approach:

Proprietary combinatorial genetics used (inaBleÂŽ) to express and demonstrate target activities of 36 independent genes in multiple configurations

Result:

Demonstrated reactions to exemplify IP strategy Customer entered multi-year bioprocess development program with Ingenza to establish large scale fermentation routes to novel products Replacing petroleum-based processes

We will

We will

UR MISSIO

We aim

Wa l l a c e B u i l d i n g , R o s l i n B i o C e n t r e , M i d l o t h i a n , e H 2 5 9 P P, U K

innovating adapting delivering world class

Te l : + 4 4 ( 0 ) 1 3 1 2 0 0 6 3 5 5 Fax: +44 (0) 131 200 6353 Email: sarah.graham@ingenza.com

biotechnology